A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular Hypertension

Open-angle Glaucoma, Ocular Hypertension Clinical Trial

Official title: A Randomized, Double-masked, Controlled Parallel Group, Multi-center Study of DE-111A (Fixed Dose Combination of Tafluprost and Timolol Eye Drops) on the Treatment of Open Angle Glaucoma or Ocular Hypertension (With Tafluprost Eye Drops as a Comparator)

Status Completed

Clinical Trial Summary

The objective of this study is to investigate whether the IOP (intraocular pressure) -lowering effect of DE-111A (preservative-free fixed dose combination of 0.0015% tafluprost and 0.5% timolol eye drops, administered one drop a time, once daily for 3 months) is superior to the monotherapy of tafluprost 0.0015% eye drops administered one drop a time, once daily for 3 months) in subjects with open-angle glaucoma or ocular hypertension in China as well as comparison of safety.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Glaucoma
• Glaucoma, Open-Angle
• Hypertension
• Ocular Hypertension
• Open-angle Glaucoma, Ocular Hypertension

• NCT number: NCT03822559
• Study type: Interventional
• Source: Santen Pharmaceutical Co., Ltd.
• Status: Completed
• Phase: Phase 3
• Start date: January 20, 2019
• Completion date: April 4, 2023